Skip to main content

New Drug Update: 2008

Buy Article:

$35.00 plus tax (Refund Policy)

Abstract:

Only 16 new therapeutic agents were marketed in the United States in 2008, the lowest number in many years. Four new drugs have been selected for consideration in this review. The uses and most important properties of each agent are considered, and a rating for each new drug is provided using the New Drug Comparison Rating (NDCR) system developed by the author.

Abbreviations: AE = Adverse event, BP = Blood pressure, MAOI = Monoamine oxidase inhibitor, MDD = Major depressive disorder, NDCR = New Drug Comparison Rating, SNRI = Serotonin and norepinephrine reuptake inhibitor, SSRI = Selective serotonin-reuptake inhibitor.

Keywords: Bystolic; Ciclesonide; Desvenlafaxine succinate; Methylnaltrexone bromide; Nebivolol hydrochloride; Omnaris; Pristiq; Relistor

Document Type: Research Article

DOI: https://doi.org/10.4140/TCP.n.2009.268

Publication date: 2009-04-01

More about this publication?
  • The Consultant Pharmacist® is the official peer-reviewed journal of the American Society of Consultant Pharmacists. It is dedicated exclusively to the medication needs of the elderly in all settings, including adult day care, ambulatory care, assisted living, community, hospice, and nursing facilities. This award-winning journal is a member benefit of ASCP. Individuals who are not members and wish to receive The Consultant Pharmacist® will want to consider joining ASCP.
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Membership Information
  • Information for Advertisers
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more